Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
Company Announcements

Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial

An update from Vaxcyte (PCVX) is now available.

Vaxcyte, Inc. revealed promising initial results from its study on VAX-31, a vaccine candidate for preventing invasive pneumococcal disease in adults over 50. The Phase 1/2 trial showed that the vaccine was safe, well-tolerated, and effective in generating an immune response, indicating potential for future use in combating this serious infection.

Learn more about PCVX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyVaxcyte management to meet with Cantor Fitzgerald
TheFlyVaxcyte price target raised to $163 from $113 at Mizuho
TheFlyVaxcyte 10.2M share Secondary priced at $103.00
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App